SCHEMBL4896825

SCHEMBL4896825

Nc1c(C(=O)NCCc2cccc(F)c2)sc2nccc(C(F)(F)F)c12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP28 Q96RU2 8/20 0.49
CHRM4 P08173 3/20 0.48
USP25 Q9UHP3 5/20 0.48
KMT2A Q03164 4/20 0.47
POLB P06746 2/20 0.47
SYK P43405 1/20 0.45
LMNA P02545 3/20 0.45
NPSR1 Q6W5P4 2/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 2/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
MEN1 O00255 3/20 0.44
MAPT P10636 2/20 0.44
USP2 O75604 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
LIMK1 P53667 1/20 0.43
TP53 P04637 1/20 0.43
FOXM1 Q08050 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4897091 0.89 LMNA (0.53) USP28CHRM4USP25KMT2APOLB
SCHEMBL27688521 0.87 USP28 (0.52) USP28CHRM4USP25KMT2APOLB
SCHEMBL4887038 0.85 USP28 (0.67) USP28CHRM4USP25KMT2APOLB
SCHEMBL4897726 0.84 USP28 (0.56) USP28CHRM4USP25KMT2APOLB
SCHEMBL4890911 0.76 USP28 (0.66) USP28CHRM4USP25KMT2APOLB
SCHEMBL4898867 0.75 USP28 (0.73) USP28CHRM4USP25KMT2APOLB
SCHEMBL4898520 0.74 USP28 (0.72) USP28CHRM4USP25KMT2APOLB
SCHEMBL4887005 0.74 USP28 (0.64) USP28CHRM4USP25KMT2APOLB
SCHEMBL4897966 0.73 USP28 (0.70) USP28CHRM4USP25KMT2APOLB
SCHEMBL27708055 0.73 USP28 (0.73) USP28CHRM4USP25KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080306107-A1 Compounds ASTRAZENECA AB (SE) 2008-12-11 US claimed
CN-101128470-A Novel compounds ASTRAZENECA AB (SE) 2008-02-20 CN claimed
US-20080306107-A1 Compounds ASTRAZENECA AB (SE) 2008-12-11 US disclosed
CN-101128470-A Novel compounds ASTRAZENECA AB (SE) 2008-02-20 CN disclosed
EP-1833834-A1 NEW COMPOUNDS AstraZeneca AB (SE) 2007-09-19 EP disclosed
WO-2006068618-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306107-A1 Compounds FURIN, PCSK9, SLC10A1 USP28 4875/4885CHRM4 942/4885USP25 4874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.